Can the CD40 rs1883832 C/T variant increase autoimmune thyroid disease susceptibility?

The CD40 rs1883832 (-1C>T) single-nucleotide polymorphism is a key genetic modifier that influences immune regulation and susceptibility to autoimmune thyroid disease.

Molecular mechanisms of CD40 regulation

• Translation initiation: The rs1883832 variant resides within the CD40 gene's Kozak consensus sequence. The C risk allele creates an optimal Kozak sequence that enhances ribosome recognition and translation initiation efficiency.
• Receptor expression: Due to this enhanced translation, carriers of the CC genotype exhibit a 13% to 35% increase in cell surface CD40 protein expression compared to carriers of the T allele.
• Downstream signaling: Higher CD40 receptor density amplifies the strength of CD40–CD40L interactions, boosting downstream NF-κB activation and B-cell helper activity. This heightened costimulatory signaling lowers the threshold for immune activation.

Clinical evidence and disease specificity

• Autoantibody responses: The amplified costimulatory signaling drives thyroid autoantibody responses, leading to persistently elevated levels of thyroid peroxidase (TPO) and thyroglobulin (Tg) autoantibodies.
• Susceptibility: Meta-analyses show that the rs1883832 C allele significantly increases susceptibility to Graves' disease, with an odds ratio (OR) ranging from 1.2 to 1.6 per risk allele.
• Phenotypic specificity: This genetic risk is highly specific to Graves' disease, which is characterized by these autoantibody responses, and does not robustly extend to Hashimoto's thyroiditis.

Bottom line

• Bottom line: The CD40 rs1883832 C allele optimizes translation efficiency and increases receptor expression by up to 35%, driving downstream costimulatory signaling that promotes thyroid autoantibody production and selectively increases Graves' disease susceptibility (OR 1.2–1.6).